Analysis of safety, tolerability, and PK data will provide information that will guide future
development of AB0024.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01323933
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Histologically or cytologically confirmed advanced malignant solid tumor that is refractory to, intolerant of, or for which no standard of therapy is available
Measurable or evaluable disease
ECOG Performance Status of ≤2
No known active central nervous system (CNS) tumors or CNS metastases
Adequate organ function
Myocardial infarction within the last 6 months of study Day 1, symptomatic congestive heart failure (New York Heart Association Classification > Class II), unstable angina, or unstable cardiac arrhythmia requiring medication
History of surgery within 28 days prior to enrollment or anticipated surgery during the study period
Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy) within 28 days of study Day 1 (six weeks for nitrosoureas, mitomycin C, antibodies, or molecular agents with t½ >10 days);
(concurrent use of hormone therapy for breast or prostate cancer is permitted)
Treatment with immune modulators including, but not limited to, cyclosporine and tacrolimus within two weeks prior to enrollment
Concurrent or prior (within 30 days of study Day 1) anticoagulation therapy; (low-dose warfarin [<2 mg/day] for prophylaxis against central venous catheter thrombosis is allowed)
Patient with tumor that is infiltrating or invading a major blood vessel
All locations for NCT01323933
United States (2)
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States, 78229
View full eligibility
Tris trial is registered with FDA with number: NCT01323933. The sponsor of the trial is Gilead Sciences and it is looking for 32 volunteers for the current phase.
Official trial title: A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB0024 in Adult Patients With Advanced Solid Tumors
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.